

Avelumab versus standard second-line treatment in MSI metastatic colorectal cancer patients : the SAMCO-PRODIGE 54 randomised phase II trial.

Julien TAIEB, Olivier BOUCHE, Thierry ANDRE, Emilie BARBIER, Pierre LAURENT-PUIG, Jérémie BEZ, Clémence TOULLEC, Christophe BORG, Violaine RANDRIAN, Ludovic EVESQUE, Stephane CORBINAIS, Hervé PERRIER, Bruno BUECHER, Frederic DI FIORE, Claire Gallois, Come LEPAGE, Farid ELHAJBI, David TOUGERON.

Julien TAIEB

Paris, France, September 12, 2022





DECLARATION OF INTERESTS

JT has received honoraria for consulting or speaker roles from :

AMGEN, Astellas, Astra-Zeneca, BMS, Merck, MSD, Novartis, Pierre Fabre, Servier





Background and goal

 Immune checkpoint inhibitors alone have failed in treating metastatic mCRC patients except those with MSI/dMMR tumours.


Grothey et al. ESMO 2018 Eng C, et al. Lancet Oncol. 2019

Only one randomized trial, in the first-line setting, showed the superiority of an anti-programmed death1 (anti-PD-1) over standard treatment.





MMR protein deficiency (IHC)




The SAMCO-PRODIGE 54 trial aimed, in the second-line setting, to evaluate efficacy and safety of an anti-programmed death ligand-1 (anti-PD-L-1) antibody in MSI/dMMR mCRC patients as compared to a second-line standard chemotherapy ± targeted therapy.





Study Design: SAMCO-PRODIGE 54





•

٠

٠

Methodology & Statistics

- National, multi-center, open-label phase II comparative trial.
- Primary endpoint: progression-free survival (PFS) according to RECIST 1.1 criteria and evaluated by investigators.
- Analyzes were planned on mITT defined as all MSI/dMMR patients with a
 positive testing with IHC (4 MMR proteins) and tumor DNA (PCR) who received
 at least on cycle of planned treatment.
- statistical hypothesis were increase of PFS in favor of avelumab arm with a HR of 0.58, with 106 events needed to demonstrate this difference and 132 patients to enroll.





Results : Baseline characteristics

 132 pts were enrolled between 04/2018 and 04/2021, 10 pts (4+6) were excluded from the mITT population (5 Microsatellite Stable, 4 did not received any treatment (including 3 deaths), 1 consent withdrawal), mITT= 122 patients.

Characteristic	Avelumab N = 61	chemotherapy N = 61
Gender (M / F)	26 / <mark>35</mark>	31 / <mark>30</mark>
Median age (IQ range)	66 (54 – 75)	67 (60 – 75)
ECOG PS (0 /1 /2-%)	44 / 46 / 10	49 / 43 / <mark>8</mark>
Right sided primary tumor (%)	87%	77%
BRAF V600E mutation (%)	46%	40%
RAS mutation (%)	23%	21%
> 5 metastases (%)	41%	44%
>1 metastatic sites (%)	46%	53%
Previous treatment (FOLFOX/FOLFIRI/Others*- %)	62/12/26	69/19/12
congross	* 5FU, capecitabine, FOLFIRINOX, CAPOX, CAPIRI	




Results: best response RECIST1.1 investigator

	Avelumab N = 61	Chemotherapy N = 61
Complete response	4 (6.5%)	3 (5%)
Partial response	14 (23%)	13 (21.3%)
ORR	18 (29.5%)	16 (26.3%)
Stable disease	25 (41%)	31 (51%)
DCR	43 (70.5%)	47 (77.3%)
Progressive disease	17 (28%)	10 (16.5%)
Time to best response (months)	2.99	1.94








PARIS ESMO

Julien TAIEB

Results: disease control duration





Results: safety profile

G3/4 adverse events, % patients	Avelumab (N = 63)	Chemotherapy (N = 64)
All grade ³ ⁄ ₄ toxicities	31.7%	53.1%
Nausea	0	1.6
Vomiting	0	1.6
Diarrhea	4.8	7.8
Stomatitis	0	3
Neutropenia	0	18.8
Neurotoxicity	0	3.2
Fatigue	0	10.9
Hypertension	1.6	10.9
Abnormal liver tests	9.5	1.6






Julien TAIEB


congress

PARIS 2022

Discussion




PRODIGE 54-SAMCO 2nd-line Avelumab













Discussion KEYNOTE 177 PRODIGE 54-SAMCO 100 90 Anti-PD-1 availability and 80 Patients selection (PS2, EDR...) 70 % 60 S 40 50 Other resistance factors? • 40 27% 25% 30 19% 20 9% 10 10 3% 0 10 12 16 18 20 22 28 0 6 8 14 24 26 30 32 12 16 20 24 28 32 36 40 44 48 52 56 60 0 8 Time (Months) Time, months N at risk Arm A Arm B No. at Risk <mark>61</mark> 61 <mark>53</mark> 50 <mark>41</mark> 28 30 20 23 22 14 20 11 9 5 3 3 2 1 1 1 1 1 19 19 18 14 14 13 12 12 12 10 10 153 96 77 72 64 60 59 55 50 42 28 16 0 0 0 69 45 35 25 21 16 12 11 8 0 154 101





Summary

- The study met its primary endpoint on PFS
- Avelumab performed better than 2nd line historical treatments
- ORR and DCR were similar between treatment arms but disease control was maintained over 18 months with avelumab in the vast majority of patients
- The use of avelumab led to lower rates of G3/4 AEs
- Resistance to ICI is a not rare in MSI/dMMR mCRC and has to be investigated further





Conclusions

The SAMCO-PRODIGE 54 randomized phase II study:

- Shows the efficacy and safety of avelumab in 2nd line treatment for dMMR/MSI mCRC
- Confirm in this randomized phase II that the use of anti-PD(L)1 remains relevant beyond 1st line not pre-treated with an immune check point inhibitor
- Indirectly suggests that dMMR/MSI mCRC should be treated as soon as possible with an ICI
- overall survival, quality of life & biomarkers analysis (tumour, blood and stools) from the SAMCO-PRODIGE 54 will be analysed and presented in future meetings in order to identify predictors of response/resistance





Acknowledgments

- Patients and their families
- David Tougeron, Marie Moreau, Jérémie Bez, Emilie Barbier, Karine le Malicot,

Cécile Girault, Thierry André and Pierre Laurent-Puig

- The FFCD as sponsor of the trial and PRODIGE intergroup
- All participating investigators across the country
- Merck Serono for partially supporting the study

Thank you for your attention



